Chemotherapy for Metastatic Borderline Phyllodes Tumors

Primary Treatment Approach

• Surgical resection or local ablative therapy of metastatic lesions should be the primary treatment approach for metastatic borderline phyllodes tumors, as chemotherapy has limited proven efficacy in this specific tumor grade, according to the National Comprehensive Cancer Network 1, 2

Critical Treatment Paradigm

• The UK guidelines for soft tissue sarcomas recommend surgery as the initial treatment strategy for metastatic phyllodes tumors given their relatively indolent nature 1
• If surgery is not feasible or disease progresses after surgical intervention, systemic chemotherapy should follow soft tissue sarcoma treatment paradigms, not breast cancer regimens, as recommended by the National Comprehensive Cancer Network 1, 2

Recommended Chemotherapy Regimens

• The Doxorubicin-Ifosfamide (AI) regimen is the recommended first-line systemic therapy for metastatic borderline/malignant phyllodes tumors, according to the National Comprehensive Cancer Network 1, 2
• Alternative regimens based on sarcoma guidelines include Gemcitabine plus docetaxel, Doxorubicin monotherapy, and Ifosfamide monotherapy, as recommended by the National Comprehensive Cancer Network 3

Critical Clinical Pitfalls to Avoid

• Phyllodes tumors require sarcoma-directed therapy, not breast cancer chemotherapy, according to the European Society for Medical Oncology 1
• Endocrine therapy has no proven efficacy and should not be used, as stated by the National Comprehensive Cancer Network 1, 2

Treatment Monitoring

• Re-evaluate after 2-3 cycles of chemotherapy and continue for 2 additional cycles if disease responds or remains stable, as recommended by the National Comprehensive Cancer Network 5, 6

Multidisciplinary Approach

• All borderline phyllodes tumors should be referred to specialist sarcoma centers for pathology review and multidisciplinary team discussion, according to the National Comprehensive Cancer Network 2
• Close collaboration between breast cancer and sarcoma multidisciplinary teams is essential for appropriate risk stratification, as recommended by the European Society for Medical Oncology 2